Mechanistic Clinical Trial of PCSK9 Inhibition for AAA
Status:
Not yet recruiting
Trial end date:
2028-11-01
Target enrollment:
Participant gender:
Summary
The goal of this mechanistic clinical trial is to assess whether lowering the low-density
lipoprotein cholesterol (LDL-C) levels in the blood with the injections of the medication
evolocumab will have any effect on the tissue or cells of patients with abdominal aortic
aneurysm (AAA). Researchers will compare participants receiving evolocumab injections to
participants receiving placebo injections to see how the tissue and cells of the aorta are
affected by changes in LDL-C levels.
Phase:
Early Phase 1
Details
Lead Sponsor:
University of Pennsylvania
Collaborators:
Amgen National Heart, Lung, and Blood Institute (NHLBI)